Why the study?
Chromogenic anti-FXa assays are the gold standard for monitoring indirect anticoagulants but vary by reagent choice, warranting evaluation of assay performance and longitudinal variation over time.
Does the choice of chromogenic anti-FXa assay method affect the measurement accuracy and variation for monitoring indirect anticoagulants?
Observational
Yes
Does the choice of chromogenic anti-FXa assay method affect the measurement accuracy and variation for monitoring indirect anticoagulants?
Significant inter-method and interlaboratory variation exists in anti-FXa assays for UFH and LMWH, particularly at concentrations below 0.35 IU/mL, which may impact clinical therapeutic ranges.
Answers are grounded in this paper and cite their sources.
Results below 0.35 IU/mL warrant caution in UFH/LMWH monitoring; leaves open standardization needs across reagents.
Objectives Chromogenic anti-activated factor X (FXa) assays are currently the "gold standard" for monitoring indirect anticoagulants. However, anti-FXa has been shown to vary according to the choice of reagents. In the present study, the performance of anti-FXa measurement was evaluated in order to gain more insight into the clinical applications. Furthermore, the longitudinal coefficient of variation (CV) was studied to investigate whether there is improvement over time. Methods Laboratory tests results were evaluated for samples spiked with unfractionated heparin (UFH), low-molecular-weight-heparin (LMWH), fondaparinux and danaparoid sodium. External quality assessment (EQA) data from multiple years were used from more than 100 laboratories. Results Comparison of the results for all methods showed significant differences in measured values between the frequently used methods (ANOVA: p < 0.001). The largest differences were observed for LMWH and UFH measurements. These differences may be caused by differences in method composition, such as the addition of dextran sulphate. Substantial interlaboratory variation in anti-FXa monitoring was observed for all parameters, particularly at low concentrations. Our results showed that below 0.35 IU/mL, the CVs for UFH and LMWH increase dramatically and results below this limit should be used with caution. Conclusions Our study demonstrates that the choice of the anti-FXa method is particularly important for UFH and LMWH measurement. The variation in measurements may have an effect on clinical implications, such as therapeutic ranges. Furthermore, the longitudinal EQA data demonstrated a constant performance and, in at least 50% of the cases, improvement in the CV% of the anti-Xa results over time.
No takes yet. Share an insight, caveat, or question.
Hollestelle et al. (2020) conducted an observational in Indirect Xa inhibitor monitoring. Chromogenic anti-activated factor X (FXa) assays vs. Different assay methods/reagents was evaluated on Differences in measured values between frequently used methods (p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: